Victory Capital Management Boosts Stake in Eli Lilly

Institutional investor increases holdings in pharmaceutical giant by 47.6% in Q3

Mar. 3, 2026 at 8:23am

Got story updates? Submit your updates here. ›

Victory Capital Management Inc. increased its stake in Eli Lilly and Company (NYSE:LLY) by 47.6% during the third quarter, according to a recent SEC filing. The firm now owns 2,309,006 shares of the pharmaceutical company's stock, making it Eli Lilly's 7th largest institutional shareholder.

Why it matters

Eli Lilly is one of the world's leading pharmaceutical companies, known for developing innovative drugs and therapies. Victory Capital's increased investment signals confidence in the company's long-term growth prospects and ability to deliver returns for shareholders.

The details

Victory Capital Management, an investment management firm, boosted its position in Eli Lilly by adding 744,868 shares during the third quarter. This increased the firm's total holdings in Eli Lilly to 2,309,006 shares, or approximately 0.24% of the company's outstanding stock. Victory Capital cited Eli Lilly's strong pipeline of new drugs and therapies as a key factor behind the increased investment.

  • Victory Capital filed its Q3 2026 13F report with the SEC on March 3, 2026, disclosing the increased Eli Lilly stake.

The players

Victory Capital Management Inc.

An investment management firm that oversees over $150 billion in client assets, with a focus on institutional and individual investors.

Eli Lilly and Company

A global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana, known for developing innovative drugs and therapies.

Got photos? Submit your photos here. ›

The takeaway

Victory Capital's increased stake in Eli Lilly underscores the pharmaceutical company's appeal to institutional investors seeking exposure to the healthcare sector. Eli Lilly's robust drug pipeline and history of innovation continue to drive investor confidence in the company's long-term growth potential.